Protein Kinase D3 Sensitizes RAF Inhibitor RAF265 in Melanoma Cells by Preventing Reactivation of MAPK Signaling

Abstract excerpt

RAS mutations occur in more than 30% of all human cancers but efforts to directly target mutant RAS signaling as a cancer therapy have yet to succeed. As alternative strategies, RAF and MEK inhibitors have been developed to block oncogenic signaling downstream of RAS. As might be expected, studies of these inhibitors have indicated that tumors with RAS or BRAF mutations display resistance RAF or MEK inhibitors....

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cellular Mechanics and Interactions
• Share to Cytokine Signaling Pathways and Interactions
• Share to Melanoma and MAPK Pathways